Glycosaminoglycans (GAGs) located on cellular membranes and the extracellular matrix (ECM) are able to interact with
chemokines and pro-inflammatory
cytokines, leading to local
cytokine/
chemokine accumulation. The tissue-bound
cytokines/
chemokines function in promoting leukocyte migration and activation, contributing to local
inflammation. Hence, targeting of GAG-
cytokine interactions may provide an avenue for the attenuation of inflammatory responses. A cationic
peptide (MC2) derived from the
heparin-binding sequence of mouse IFN-gamma was previously shown by our laboratory to delay allograft rejection in an animal model. In order to further investigate potential anti-inflammatory properties of the
MC2 peptide, we have studied its activity in an acute peritoneal
inflammation model. Groups of C57Bl/6 mice were injected intraperitoneally with either ConA or thioglycollate and treated with saline (control), the
MC2 peptide or two control cationic
peptides, poly-
l-lysine (PLL) and
poly-l-arginine (PLA). Treatment with the
MC2 peptide, but not PLA or PLL, resulted in statistically significant reductions in total cell numbers, concentration of total
proteins and concentrations of pro-inflammatory
cytokines (
TNFalpha, IL-6 or IL-1 beta) in peritoneal lavage fluids, without alterations to the qualitative cellular composition of the exudate. These results suggest that targeting GAG-
cytokine interaction is a viable approach to reduce
inflammation.